2015 AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY
V. Benoit, B. Seignères, M. Lesénéchal, N. Cayet, C. Tourneur, M. Richard, M.C. Bastide, C. Pretis, C. Pease, B. Beyaert, J.M. Dugua, M. Hausmann
bioMérieux S.A., Marcy l’Etoile, France
Background and Objectives
While immunoassays remain the mainstay for the automated, routine dia-gnostics testing of patient samples, early clinical diagnosis often hinges on the ability to reliably measure medically relevant biomarkers at very low-concentrations, beyond the reach of current conventional immunoanalyzer capability. SimoaTM (Single Molecule Array) technology provides the ability to mea-sure protein analytes with unprecedented sensitivity, down to the femto-molar range. Quanterix’s HD-1 system offers full automation of Simoa digi-tal immunoassay technology for life science research applications. This RUO (Research Use Only) system is available with a menu of assays (currently about 30) showing up to 1000x higher sensitivity compared to current best-in-class automated analog immunoassays. In the prospect of developing an IVD-compliant (regulatory approved) ver-sion of the Simoa system, key analytical performance characteristics were evaluated, based on guidelines from the Clinical and Laboratory Stan-dards InstituteTM (CLSI), using two prototype assays for the detection of PSA (prostate-specific antigen) and HIV p24 (human immunodeficiency vi-rus p24 antigen) in human serum or plasma. In the context of these stu-dies, the two prototype assays served as tools for system performance evaluation.
Related Posts
Neurology
Comparative Spatial Analyses of the Tumor Immune Landscape in Mouse Models of Glioblastoma Using the PhenoCode Discovery Mouse Neuro Panel and Customized Markers
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Development of a Spatial Metabolic Map of Immunotherapy Sensitive and Resistant Cutaneous Skin Carcinoma
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Spatial Immunometabolic Profiling of Non-Small Cell Lung Cancer Reveals Distinct Immune Exclusion Patterns and Functional Niches
Analytical validation of a multiplex immunofluorescence 7-Biomarker Immunoprint® assay on the Akoya PhenoImager HT platform for stage I/II Melanoma
Neurology
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Clinical validation of the LucentAD p-Tau 217 as a lab developed test (LDT) for clinical use
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Discovering novel plasma biomarkers for ischemic stroke: Lipidomic and metabolomic analyses in an aged mouse model
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…